Diabetes can damage nerves throughout the body. Diabetic neuropathy is the most common complication of diabetes mellitus numbness, pain in the hands, legs and feet, weakness of the muscles in the feet and hands, sharp pains, and insensitivity to pain or temperature changes are the common symptoms of diabetic neuropathy. Peripheral, autonomic, focal, and proximal neuropathy are the types of diabetic neuropathy. Among them, peripheral neuropathy is the most common type in which feet and legs are affected first then followed by hands and arms. Diabetic neuropathy can be extremely painful and cannot be cured. Pregabalin, amitriptyline and citalopram are some of the first-line treatment for painful diabetic neuropathy.
The U.S. diabetic neuropathy market is estimated to be valued at US$ 1,759.4 million in 2022 and is expected to exhibit a CAGR of 5.2% during the forecast period (2022-2030).
Figure 1. U.S. Diabetic Neuropathy Share (%), by Type, 2022
U.S. Diabetic Neuropathy Market - Driver
Increasing inorganic strategies such as product approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to boost the growth of the U.S. diabetic neuropathy market. For instance, in December 2019, Averitas Pharma, Inc., a pharmaceutical company, announced that they had received approval from U.S. Food and Drug Administration for QUTENZA, the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. QUTENZA is the first and only topical, non-systemic, non-opioid pain treatment for diabetic peripheral neuropathy. A single local topical treatment with QUTENZA may provide up to 3 months of relief from the nerve pain.
|Base Year:||2021||Market Size in 2022:||US$ 1,759.4 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||5.2%||2030 Value Projection:||US$ 2,635.9 Mn|
Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.
|Restraints & Challenges:||
Figure 2. U.S. Diabetic Neuropathy Share (%), by Route of Administration, 2022
U.S. Diabetic Neuropathy Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the U.S. diabetic neuropathy market due to the increasing risk of peripheral neuropathy from COVID-19. For instance, according to the data published in March 2022, by Washington University School of Medicine, COVID-19 patients are extremely at higher risk of experiencing symptoms of peripheral neuropathy, such as pain, numbness and tingling in the hands and feet, which, in turn, increased the sales of neuropathic treatment drugs, thus positively impacting the global diabetic neuropathy market growth.
U.S. Diabetic Neuropathy Market: Key Developments
Adoption of inorganic growth strategies such as drug approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to drive the U.S. diabetic neuropathy market. For instance, in July 2019, Alembic Pharmaceuticals Limited, a pharmaceutical company, announced that they had received an approval from U.S. Food and Drugs Administration for or Pregabalin capsules, an oral and extended-release tablets, which indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older.
U.S. Diabetic Neuropathy Market: Restraint
High cost treatment of diabetic neuropathy in the U.S. is expected to hamper the growth of the U.S. diabetic neuropathy market over the forecast period. For instance, in February 2020, according to the data published by National Center for Biotechnology Information, there is a significant increase in health care costs among a large number of patients with painful diabetic neuropathy (pDPN). The total median healthcare cost was US$ 16,795 in the first year after diagnosis and patients with painful diabetic neuropathy (pDPN) spent 3 times more as much on medications.
U.S. Diabetic Neuropathy Market - Key Players
Major players operating in the U.S. diabetic neuropathy market include Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.
Diabetic neuropathy is a serious and common complication of type 1 and type 2 diabetes. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower leg, it develops slowly, sometimes over the course of decades. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. Peripheral neuropathy is the most common form of neuropathy. Over time, high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage your nerves. High blood glucose levels can also damage the small blood vessels that nourishes the nerves with oxygen and nutrients. There is no cure for diabetic neuropathy but the nerve pain can be managed with medication and exercise.
Increasing adoption of inorganic strategies such as collaborative agreement by key market players is expected to drive the U.S. diabetic neuropathy market over the forecast period. For instance, in June 2020, NeuroMetrix, Inc., a medical device company, announced that they had signed a collaborative agreement with BioMedix, a manufacturer of diagnostic and surgical equipment, to comarket DPNCheck for peripheral neuropathy detection within medicare advantage. This agreement will provide complementary diagnostic tests to physicians and health plans by combining results from multiple diagnostic tests into one data exchange file for the electronic medical record system.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.